Literature DB >> 18052241

Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin.

Ping Zhou1, Li-Ping Li, Shu-Qing Luo, Hui-Di Jiang, Su Zeng.   

Abstract

Luteoin is one of the main flavones and the crucial effective component of peanut hull extract (PHE). The present paper aims to elucidate the absorption mechanism of luteolin and clarify whether its absorption occurs primarily at a specific site of the intestine by an in situ single-pass intestinal perfusion (SPIP) model. Moreover, the paper investigates the difference in absorption of luteolin when it is administered in PHE form and as pure luteolin by the SPIP model and in vivo pharmacokinetics studies. Results showed that the effective permeability ( P eff) and absorption rate constant ( k a) of pure luteolin(5.0 microg/mL) in duodenum and jejunum were not significantly different, but markedly higher than that in the colon and ileum. The P eff and k a of luteolin in jejunum were concentration-independent, and the ATP inhibitor (DNP) did not influence P eff and k a of pure luteolin. However, the P eff and k a of luteolin in PHE were significantly greater than that of pure luteolin. The pharmacokinetics study showed that following oral administration of a single dose of pure luteolin (14.3 mg/kg) or PHE (= 14.3 mg/kg of luteolin) in rats, the peak concentration of luteolin in plasma ( C max) and the area under the concentration curve (AUC) for pure luteolin were 1.97 +/- 0.15 microg/mL and 10.7 +/- 2.2 microg/mL.h, respectively. These parameters were significantly lower than those of the PHE group ( P < 0.05), C max = 8.34 +/- 0.98 microg/mL and AUC = 20.3 +/- 1.3 microg/mL.h, respectively. It can be concluded that luteolin is absorbed passively in the intestine of rats and that its absorption is more efficient in the jejunum and duodenum than in the colon and ileum. The bioavailability of luteolin in PHE form is significantly greater than that of pure luteolin.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18052241     DOI: 10.1021/jf072612+

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  18 in total

1.  Identification of the Flavonoid Luteolin as a Repressor of the Transcription Factor Hepatocyte Nuclear Factor 4α.

Authors:  Juan Li; Jun Inoue; Jung-Min Choi; Shugo Nakamura; Zhen Yan; Shinya Fushinobu; Haruhiko Kamada; Hisanori Kato; Tsutomu Hashidume; Makoto Shimizu; Ryuichiro Sato
Journal:  J Biol Chem       Date:  2015-08-13       Impact factor: 5.157

Review 2.  Flavones: Food Sources, Bioavailability, Metabolism, and Bioactivity.

Authors:  Gregory L Hostetler; Robin A Ralston; Steven J Schwartz
Journal:  Adv Nutr       Date:  2017-05-15       Impact factor: 8.701

3.  Luteolin alleviates ulcerative colitis through SHP-1/STAT3 pathway.

Authors:  Bo-Lin Li; Dan-Yang Zhao; Peng-Li Du; Xiao-Tian Wang; Qian Yang; Yan-Ru Cai
Journal:  Inflamm Res       Date:  2021-05-20       Impact factor: 4.575

4.  Endocrine disrupting activities of the flavonoid nutraceuticals luteolin and quercetin.

Authors:  Steven K Nordeen; Betty J Bona; David N Jones; James R Lambert; Twila A Jackson
Journal:  Horm Cancer       Date:  2013-07-09       Impact factor: 3.869

Review 5.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 6.  Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition.

Authors:  Yaseen Hussain; Jing Hao Cui; Haroon Khan; Michael Aschner; Gaber El-Saber Batiha; Philippe Jeandet
Journal:  Med Oncol       Date:  2021-05-05       Impact factor: 3.064

7.  Flavone deglycosylation increases their anti-inflammatory activity and absorption.

Authors:  Gregory Hostetler; Ken Riedl; Horacio Cardenas; Mayra Diosa-Toro; Daniel Arango; Steven Schwartz; Andrea I Doseff
Journal:  Mol Nutr Food Res       Date:  2012-02-20       Impact factor: 5.914

8.  Breast cancer resistance protein-mediated efflux of luteolin glucuronides in HeLa cells overexpressing UDP-glucuronosyltransferase 1A9.

Authors:  Lan Tang; Ye Li; Wei-Ying Chen; Shan Zeng; Ling-Na Dong; Xiao-Juan Peng; Wen Jiang; Ming Hu; Zhong-Qiu Liu
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

9.  Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.

Authors:  Zhuan Hong; Xiang Cao; Na Li; Yizhou Zhang; Lei Lan; Yi Zhou; Xiaolong Pan; Lei Shen; Zhimin Yin; Lan Luo
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

10.  Preparation and characterization of monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) micelles for the solubilization and in vivo delivery of luteolin.

Authors:  Jin-Feng Qiu; Xiang Gao; Bi-Lan Wang; Xia-Wei Wei; Ma-Ling Gou; Ke Men; Xing-Yu Liu; Gang Guo; Zhi-Yong Qian; Mei-Juan Huang
Journal:  Int J Nanomedicine       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.